TY  - JOUR
  - Campion, A,Casey, PG,Field, D,Cotter, PD,Hill, C,Ross, RP
  - 2013
  - February
  - BMC Microbiology
  - In vivo activity of Nisin A and Nisin V against Listeria monocytogenes in mice
  - Validated
  - WOS: 47 ()
  - Antimicrobial Lantibiotic Bacteriocin Peptide engineering Mutagenesis Nisin RESISTANT STAPHYLOCOCCUS-AUREUS GRAM-POSITIVE PATHOGENS LACTOCOCCUS-LACTIS ANTIMICROBIAL PEPTIDES ENHANCED ACTIVITY PORE FORMATION LANTIBIOTICS BIOSYNTHESIS ANTIBIOTICS VITRO
  - 13
  - Background: Lantibiotics are post-translationally modified antimicrobial peptides, of which nisin A is the most extensively studied example. Bioengineering of nisin A has resulted in the generation of derivatives with increased in vitro potency against Gram-positive bacteria. Of these, nisin V (containing a Met21Val change) is noteworthy by virtue of exhibiting enhanced antimicrobial efficacy against a wide range of clinical and food-borne pathogens, including Listeria monocytogenes. However, this increased potency has not been tested in vivo.Results: Here we address this issue by assessing the ability of nisin A and nisin V to control a bioluminescent strain of Listeria monocytogenes EGDe in a murine infection model.More specifically, Balb/c mice were infected via the intraperitoneal route at a dose of 1 x 10(5) cfu/animal and subsequently treated intraperitoneally with either nisin V, nisin A or a PBS control. Bioimaging of the mice was carried out on day 3 of the trial. Animals were then sacrificed and levels of infection were quantified in the liver and spleen.Conclusion: This analysis revealed that nisin V was more effective than Nisin A with respect to controlling infection and therefore merits further investigation with a view to potential chemotherapeutic applications.
  - 10.1186/1471-2180-13-23
DA  - 2013/02
ER  - 

@article{V243943754,
   = {Campion,  A and Casey,  PG and Field,  D and Cotter,  PD and Hill,  C and Ross,  RP },
   = {2013},
   = {February},
   = {BMC Microbiology},
   = {In vivo activity of Nisin A and Nisin V against Listeria monocytogenes in mice},
   = {Validated},
   = {WOS: 47 ()},
   = {Antimicrobial Lantibiotic Bacteriocin Peptide engineering Mutagenesis Nisin RESISTANT STAPHYLOCOCCUS-AUREUS GRAM-POSITIVE PATHOGENS LACTOCOCCUS-LACTIS ANTIMICROBIAL PEPTIDES ENHANCED ACTIVITY PORE FORMATION LANTIBIOTICS BIOSYNTHESIS ANTIBIOTICS VITRO},
   = {13},
   = {{Background: Lantibiotics are post-translationally modified antimicrobial peptides, of which nisin A is the most extensively studied example. Bioengineering of nisin A has resulted in the generation of derivatives with increased in vitro potency against Gram-positive bacteria. Of these, nisin V (containing a Met21Val change) is noteworthy by virtue of exhibiting enhanced antimicrobial efficacy against a wide range of clinical and food-borne pathogens, including Listeria monocytogenes. However, this increased potency has not been tested in vivo.Results: Here we address this issue by assessing the ability of nisin A and nisin V to control a bioluminescent strain of Listeria monocytogenes EGDe in a murine infection model.More specifically, Balb/c mice were infected via the intraperitoneal route at a dose of 1 x 10(5) cfu/animal and subsequently treated intraperitoneally with either nisin V, nisin A or a PBS control. Bioimaging of the mice was carried out on day 3 of the trial. Animals were then sacrificed and levels of infection were quantified in the liver and spleen.Conclusion: This analysis revealed that nisin V was more effective than Nisin A with respect to controlling infection and therefore merits further investigation with a view to potential chemotherapeutic applications.}},
   = {10.1186/1471-2180-13-23},
  source = {IRIS}
}